Please provide your email address to receive an email when new articles are posted on . “The efficacy of SARS-CoV-2 vaccines in patients treated with immunosuppressive therapies remains uncertain. ...

Intensified or accelerated dosing regimens with infliximab (Remicade) did not improve outcomes compared with the standard regimen in patients with steroid-refractory acute severe ulcerative colitis ...

Please provide your email address to receive an email when new articles are posted on . Under Medicare Part D drug benefits, the biosimilar infliximab-dyyb was only 18% less expensive than the ...

Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, according to research ...

Infliximab is a medication used to reduce the symptoms and signs of several chronic inflammatory disorders. It is approved for the treatment of Crohn’s disease, rheumatoid arthritis, psoriasis, ...

The study, with a small sample size, said most patients who take infliximab for more than 6 years report continued efficacy. Infliximab can be safe and effective as a long-term therapy in people with ...

Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for ...

Infliximab is an efficacious treatment for rheumatoid arthritis (RA). The recommended treatment schedule, however, is unsatisfactory in a substantial subset of patients. This study was an open-label ...

Infliximab is a monoclonal antibody that is administered intravenously to treat patients with chronic inflammatory diseases including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, plaque ...

Studies have shown that treatment with tumor necrosis factor inhibitors results in sustained improvements in the signs and symptoms of rheumatoid arthritis (RA). Infliximab, a chimeric monoclonal anti ...

An infliximab biosimilar (infliximab-axxq) delivered via subcutaneous injection was superior to intravenous vedolizumab (Entyvio) for induction and maintenance therapy of Crohn's disease (CD), ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of infliximab, having considered evidence on the nature of acute exacerbations of severely active ulcerative ...